ABMD Reports FQ4 Results Inline With Preannouncement
Analysts at Susquehanna Financial maintain their "neutral" rating on ABIOMED Inc (NASDAQ: ABMD), while raising their estimates for the company.
ABIOMED has reported its FQ3 results inline with its preannouncement. However, ABMD reported narrower-than-expected net losses for the quarter, the analysts say. “Despite improving commercial Impella sales, the number of patients enrolled in the company’s Protect II trial continues to decline on a quarterly basis,” the analysts add.
ABMD has reduced its FY10 revenue guidance to $84 million-$86 million from $86 million-$91 million. ABMD’s stock is fairly valued at present, the analysts add. Susquehanna Financial has raised its EPS estimate for FY10 from -$0.69 to -$0.67.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
